Visionary Innovation
Our Treatment Candidates
Acute Optic
Neuritis
Up to 8 in 100,000 people worldwide suffer from acute optic neuritis1, a disease that can lead to permanent visual impairment with no specific therapy approved and mostly occurring in young adults
Privosegtor, a novel peptoid small molecule that penetrates the blood brain and retinal barrier, has the potential to become the first neuroprotective therapy for optic neuropathies and other neuro-ophthalmic diseases.
Privosegtor
Privosegtor, a novel peptoid small molecule that penetrates the blood brain and retinal barrier, has the potential to become the first neuroprotective therapy for optic neuropathies and other neuro-ophthalmic diseases.
Non-arteritic Anterior Ischemic Optic Neuropathy
Up to 10 in 100,000 people worldwide suffer from non-arteritic anterior optic neuropathy (NAION)2, an acute optic nerve disorder with no approved therapy and permanent visual impairment in > 60% of patients3.
Privosegtor, a novel peptoid small molecule that penetrates the blood brain and retinal barrier, has the potential to become the first neuroprotective therapy for optic neuropathies and other neuro-ophthalmic diseases.
Privosegtor
Privosegtor, a novel peptoid small molecule that penetrates the blood brain and retinal barrier, has the potential to become the first neuroprotective therapy for optic neuropathies and other neuro-ophthalmic diseases.
Diabetic Macular
Edema
~37 million people worldwide suffer from diabetic macular edema (DME)4,5, a leading cause of preventable blindness in working-age adults6.
OCS-01, an OPTIREACH® formulation of high concentration dexamethasone eye drop, has the potential to become the first non-invasive treatment for DME and aims to address unmet medical needs for earlier treatment intervention and patients inadequately controlled on the current standard of care.
OCS-01
OCS-01, an OPTIREACH® formulation of high concentration dexamethasone eye drop, has the potential to become the first non-invasive treatment for DME and aims to address unmet medical needs for earlier treatment intervention and patients inadequately controlled on the current standard of care.
Dry Eye Disease
>110 million people worldwide7 suffer from dry eye disease (DED), a multifactorial disease with a dissatisfied and heterogeneous patient population8.
Licaminlimab, an anti-TNFα eye drop candidate specifically designed to treat ocular inflammation, has the potential to transform the treatment paradigm of DED with a precision medicine approach.
Licaminlimab
Licaminlimab, an anti-TNFα eye drop candidate specifically designed to treat ocular inflammation, has the potential to transform the treatment paradigm of DED with a precision medicine approach.
Privosegtor, OCS-01 and Licaminlimab are investigational drugs and their safety or efficacy has not been established and they have not received regulatory approval for commercial use in any country.
See What
“Visionary Innovation”
Means To Us
OUR APPROACH
Riad Sherif, M.D., Chief Executive Officer, Oculis
Visionary Innovation to Deliver Breakthrough Therapies
At the heart of our visionary innovation is a bold commitment to rethink what’s possible for patients. Guided by unmet medical needs and grounded in cutting-edge science, we are in pursuit of health breakthroughs that go beyond incremental change. By redefining how we understand complex diseases and with a relentless focus on highly differentiated development opportunities, we aim to transform treatment approaches and bring a lasting impact to the lives of patients.
Neuro-ophthalmic and ophthalmic innovations in development
Meet the team dedicated to making a real difference in patients’ lives
Our innovative pipeline has the potential to address key unmet medical needs in neuro-ophthalmology and ophthalmology with treatments that are highly differentiated and have the potential to completely change the current treatment paradigms. I am confident that our dedication to developing transformative innovations, our patient-centric approach, and our focus on operational excellence will ultimately make a real difference in patients’ lives.